Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.50 |
| ▸ | ADK | P55263 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19537076 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL16373988 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL21006387 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL19535607 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL17109566 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL3234238 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL3229893 | 1.00 | PRMT5 (0.50) | PRMT5WDR77ADKADORA2AMETTL3 | |
| SCHEMBL21008034 | 0.91 | PRMT5 (0.47) | PRMT5WDR77ADKADORA2AMETTL3 | |
| Salicylic Acid SCHEMBL3238127 | 0.88 | PRMT5 (0.42) | PRMT5WDR77ADKADORA2A | |
| SCHEMBL19379664 | 0.88 | ADORA2A (0.48) | PRMT5WDR77ADKADORA2AMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4491232-A2 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | Emory University (US) | 2025-01-15 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-05-23 | — | — | US | claimed |
| CN-114867351-B | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-04-23 | — | — | CN | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | claimed |
| EP-4017501-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| US-8278282-B2 | Nucleoside analogs for treatment of viral infections | NOVARTIS AG (CH) | 2012-10-02 | — | — | US | claimed |
| EP-2132216-B1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131167-A2 | BISTABLE MAGNETIC ACTUATOR | JOHNSON ELECTRIC DRESDEN GMBH (DE) | 2011-10-27 | — | — | WO | claimed |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2010-09-09 | — | — | US | claimed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | claimed |
| WO-2010015643-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| EP-2132216-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | Novartis Pharma AG. (CH) | 2009-12-16 | — | — | EP | claimed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | PRMT5 3184/4885WDR77 4066/4885ADK 470/4885 |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | MAVS, HAVCR2, SAMHD1 | PRMT5 1421/4885WDR77 842/4885ADK 283/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | PRMT5 2463/4885WDR77 1820/4885ADK 1637/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | PRMT5 4434/4885WDR77 3228/4885ADK 4798/4885 |
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | PRMT5 1914/4885WDR77 3894/4885ADK 3634/4885 |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | PRMT5 2436/4885WDR77 2039/4885ADK 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.